Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Kala Pharmaceuticals ( (KALA) ) is now available.
On September 29, 2025, Kala Pharmaceuticals received a notice of default from Oxford Finance LLC regarding a Loan and Security Agreement dated May 4, 2021. The notice declared that due to a material adverse change, all obligations under the agreement were immediately due, totaling $29.1 million plus additional interest and expenses.
The most recent analyst rating on (KALA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Kala Pharmaceuticals stock, see the KALA Stock Forecast page.
Spark’s Take on KALA Stock
According to Spark, TipRanks’ AI Analyst, KALA is a Underperform.
Kala Pharmaceuticals faces significant financial difficulties, marked by declining revenues and heavy reliance on debt, which pose serious risks. The technical analysis reflects a strong downtrend, with the stock being oversold, adding to the negative outlook. Valuation is unattractive due to negative earnings and the lack of a dividend, further weighing down the stock’s appeal.
To see Spark’s full report on KALA stock, click here.
More about Kala Pharmaceuticals
Kala Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases. The company primarily targets unmet medical needs in ophthalmology.
Average Trading Volume: 868,395
Technical Sentiment Signal: Sell
Current Market Cap: $14.36M
Learn more about KALA stock on TipRanks’ Stock Analysis page.